Thursday 19th May
In response to today’s release of Lord O’Neill’s AMR review, Dr Peter Jackson, Chair of the AMR Centre Steering Group commented: “The AMR Centre Steering Committee welcomes the O’Neill Review and the continued global focus on tackling AMR. The report highlights the necessity for Governments worldwide and industry to do more together to plug the innovation gap and develop new antibiotics as a priority.
“A key reason for this gap as identified by the Review is the lack of seed funding for SMEs wanting to research new antibiotics, combined with the existing commercial models which do not incentivise research in this area.
“The AMR Centre Steering Committee, made up of both public and private sector partners, has recently put forward a proposal to the UK government which will help to address this gap, using the state of the art facilities at Alderley Park in Cheshire as the base for research designed to achieve clinical proof of concept with at least one new antibiotic in the next five years, and deliver significant returns to the taxpayer.
“We call on the Government to accelerate this funding so that the UK can maintain its leadership position in addressing AMR, and save millions of lives worldwide.”
About the AMR Centre
The UK has created a world-leading R&D centre as a major element in the global fight against AMR, based at the state-of-the-art Alderley Park campus, which has an available highly skilled workforce and emerging cluster of SMEs targeting AMR.
Following meetings with the Chancellor George Osborne and Commercial Secretary to the Treasury Jim O’Neill, a consortium of public and private sector partners joined together to create a proposal for an AMR research centre which was awarded £4 million as part of the 2015 Spending Review, subject to the approval of a successful business case, which is currently under consideration by the Department of Health.
The steering group includes Manchester Science Partnerships (the owners of Alderley Park), Cheshire East Council, RedX Pharma, the Northern Health Sciences Alliance, The University of Manchester, the N8 group of Northern Universities and Acceleris corporate finance.
The AMR Centre aims to address the urgent need for new treatments by committing to deliver at least five new antibiotics into international clinical trials, and achieving at least one successful clinical proof of concept study by 2022.
It will also initiate international AMR research efforts, in particular developing collaborations with companies and organisations in the USA, the EU, China and India.
About Dr Peter Jackson
Dr Peter Jackson is Chair of the AMR Centre Steering Group and an experienced life sciences entrepreneur, having been the co-founder of three biopharma ventures:
∙ ADC Biotechnology – focused on production of new antibody-based cancer therapeutics;
∙ Yprotech Ltd – focused on development of new chemical processes for pharmaceuticals and agrochemicals;
∙ RedX Pharmaceuticals – an emerging pharmaceutical company focused on developing new immunotherapy, oncology and anti-infective drugs.
Pete has over 25 years in the sector, previously holding senior executive roles as a Commercial Director and then head of Avecia’s Pharmaceutical Products business unit, following senior commercial and R&D positions at Zeneca and ICI.